MX2015013255A - Metodos para tratar cancer colorrectal. - Google Patents

Metodos para tratar cancer colorrectal.

Info

Publication number
MX2015013255A
MX2015013255A MX2015013255A MX2015013255A MX2015013255A MX 2015013255 A MX2015013255 A MX 2015013255A MX 2015013255 A MX2015013255 A MX 2015013255A MX 2015013255 A MX2015013255 A MX 2015013255A MX 2015013255 A MX2015013255 A MX 2015013255A
Authority
MX
Mexico
Prior art keywords
colorectal cancer
methods
treating
treating colorectal
smad7
Prior art date
Application number
MX2015013255A
Other languages
English (en)
Other versions
MX363746B (es
Inventor
Giovanni Monteleone
Salvatore Bellinvia
Viti Francesca
Original Assignee
Nogra Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nogra Pharma Ltd filed Critical Nogra Pharma Ltd
Publication of MX2015013255A publication Critical patent/MX2015013255A/es
Publication of MX363746B publication Critical patent/MX363746B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

En la presente se describen métodos para tratar y/o prevenir cáncer colorrectal usando un inhibidor específico de la expresión o función de SMAD7; también se describen composiciones farmacéuticas que contienen un inhibidor de SMAD7 para tratar y/o prevenir cáncer colorrectal y fabricar medicamentos que contengan un inhibidor de SMAD7 que se va a utilizar en el tratamiento y/o prevención de cáncer colorrectal.
MX2015013255A 2013-03-15 2014-03-14 Oligonucleótidos antisentido de smad7 para el tratamiento de cáncer colorrectal. MX363746B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361790488P 2013-03-15 2013-03-15
US201361847287P 2013-07-17 2013-07-17
PCT/EP2014/055195 WO2014140333A1 (en) 2013-03-15 2014-03-14 Methods of treating colorectal cancer

Publications (2)

Publication Number Publication Date
MX2015013255A true MX2015013255A (es) 2015-12-15
MX363746B MX363746B (es) 2019-04-01

Family

ID=50390057

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015013255A MX363746B (es) 2013-03-15 2014-03-14 Oligonucleótidos antisentido de smad7 para el tratamiento de cáncer colorrectal.

Country Status (11)

Country Link
EP (1) EP2970419B8 (es)
JP (2) JP6502863B2 (es)
KR (1) KR102232623B1 (es)
CN (1) CN105008394B (es)
AU (1) AU2014229985B2 (es)
CA (1) CA2903597C (es)
ES (1) ES2673209T3 (es)
MX (1) MX363746B (es)
NZ (1) NZ711564A (es)
RU (1) RU2674147C2 (es)
WO (1) WO2014140333A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
SI3121280T1 (sl) 2008-11-13 2025-08-29 Nogra Pharma Limited Antismiselne sestave in postopki za njihovo izdelavo ter uporabo
JP6389122B2 (ja) 2011-09-15 2018-09-12 ノグラ ファーマ リミテッド 抗ｓｍａｄ７治療に対する応答性をモニターするための方法
CN107252492A (zh) 2012-04-18 2017-10-17 诺格尔制药有限公司 治疗糖尿病和/或促进胰岛移植后存活的方法
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
CA2948411A1 (en) 2014-05-09 2015-11-12 Nogra Pharma Limited Methods for treating inflammatory bowel disease
KR20170069262A (ko) 2014-10-17 2017-06-20 노그라 파마 리미티드 Smad7 안티센스 올리고뉴클레오티드로 대상체를 치료하기 위한 방법 및 조성물
CA3000195A1 (en) * 2015-09-30 2017-04-06 Celgene Alpine Investment Company Ii, Llc Tlr modulators and methods of use
WO2017147276A1 (en) 2016-02-23 2017-08-31 Celgene Corporation Methods of treating intestinal fibrosis using smad7 inhibition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159697A (en) * 2000-01-19 2000-12-12 Isis Pharmaceuticals, Inc. Antisense modulation of Smad7 expression
ITRM20030149A1 (it) * 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
ITRM20030393A1 (it) * 2003-08-11 2005-02-12 Giuliani Spa Uso di oligonucleotidi (odn) antisenso per smad7 per il trattamento delle patologie mediate dal fattore di trascrizione nucleare nf-kb.
US7402574B2 (en) * 2004-03-12 2008-07-22 Avi Biopharma, Inc. Antisense composition and method for treating cancer
US20080114287A1 (en) * 2006-11-14 2008-05-15 Kar Neng Lai Ultrasound Microbubble Mediated Genes Delivery System
SI3121280T1 (sl) * 2008-11-13 2025-08-29 Nogra Pharma Limited Antismiselne sestave in postopki za njihovo izdelavo ter uporabo
UA107562C2 (uk) * 2008-12-05 2015-01-26 Спосіб лікування псоріазу
JP6389122B2 (ja) * 2011-09-15 2018-09-12 ノグラ ファーマ リミテッド 抗ｓｍａｄ７治療に対する応答性をモニターするための方法

Also Published As

Publication number Publication date
RU2015140572A3 (es) 2018-03-21
JP2016517401A (ja) 2016-06-16
RU2015140572A (ru) 2017-04-24
ES2673209T3 (es) 2018-06-20
AU2014229985A1 (en) 2015-09-10
CA2903597A1 (en) 2014-09-18
MX363746B (es) 2019-04-01
CN105008394A (zh) 2015-10-28
RU2674147C2 (ru) 2018-12-05
CA2903597C (en) 2023-04-04
KR20150131260A (ko) 2015-11-24
NZ711564A (en) 2020-04-24
WO2014140333A1 (en) 2014-09-18
EP2970419B8 (en) 2019-12-11
JP2019026649A (ja) 2019-02-21
HK1219489A1 (en) 2017-04-07
JP6502863B2 (ja) 2019-04-17
CN105008394B (zh) 2021-10-22
ES2673209T8 (es) 2020-02-12
AU2014229985B2 (en) 2018-12-13
KR102232623B1 (ko) 2021-03-26
EP2970419A1 (en) 2016-01-20
EP2970419B1 (en) 2018-05-09

Similar Documents

Publication Publication Date Title
ZA202308495B (en) Pharmaceutical compositions of therapeutically active compounds
NZ711564A (en) Methods of treating colorectal cancer
PH12019502810A1 (en) Bicyclic heterocycles as fgfr inhibitors
ZA202208792B (en) Methods of treating and preventing graft versus host disease
MX2016007801A (es) Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.
ZA201700572B (en) Therapeutically active compounds and their methods of use
PH12016500330B1 (en) Certain chemical entities, compositions, and methods
MX369691B (es) Inhibidores de glutaminasa y métodos de empleo.
EP3065772A4 (en) Combinations of checkpoint inhibitors and therapeutics to treat cancer
IL239453A0 (en) Preparations and methods for treating cancer using bacteria
GEP20186818B (en) Cdk8/cdk19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer
MX2016004678A (es) Composiciones para el tratamiento del cancer.
SG194469A1 (en) Tetrahydroquinoline derivatives useful as bromodomain inhibitors
PH12016501788A1 (en) Pharmaceutical compositions of therapeutically active compounds
MX377593B (es) Composiciones para usar en el tratamiento de cáncer renal.
MX2015013021A (es) 5-bromo-indirrubinas.
EP3010504A4 (en) Methods and compositions to treat cancer
EP4385563A3 (en) Dosage forms and therapeutic uses l-4-chlorokynurenine
MY182434A (en) Certain chemical entities, compositions, and methods
ZA201606135B (en) Pharmaceutical compositions of therapeutically active compounds

Legal Events

Date Code Title Description
FG Grant or registration